NutriBand Inc. 8-K

What Happened
NutriBand Inc. announced on June 1, 2026 that it entered into an amended three-year credit line facility providing up to $5,000,000 in financing. The new facility replaces the $5,000,000 facility entered March 19, 2023 (which was scheduled to expire July 13, 2026). Drawdowns under the amended line bear interest at 7% per annum and the lender does not have the right to convert outstanding amounts into common stock. The company stated the facility is to finance activities through FDA approval and into commercial-scale manufacturing for its patented lead product, AVERSA™ Fentanyl.

Key Details

• Facility size: $5,000,000; term: three years (amended on June 1, 2026).
• Interest rate: 7.0% per annum on drawdowns.
• No lender conversion: amounts outstanding under the line cannot be converted into common stock.
• Purpose: financing through FDA approval and commercialization/manufacturing of AVERSA™ Fentanyl.

Why It Matters
This amendment secures a defined source of near-term liquidity for NutriBand as it advances its lead product through regulatory approval and scales manufacturing—critical milestones for future revenue. Investors should note the 7% cash interest cost and that the financing is non-dilutive (non-convertible), which preserves equity but increases interest expense. Monitor future disclosures for actual drawdowns, cash runway updates, FDA progress for AVERSA™ Fentanyl, and any additional financing or covenant details.